Associations between single nucleotide polymorphisms in cellular viral receptors and attachment factor-related genes and humoral immunity to rubella vaccination

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Haralambieva, Iana H ^a   Lambert, Nathaniel D ^a   Ovsyannikova, Inna G ^a   Kennedy, Richard B ^a   Larrabee, Beth R ^a   Pankratz, V Shane ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD209 ANTIGEN; INTERLEUKIN 6; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NECTIN 2; NEUTRALIZING ANTIBODY; RETINOIC ACID RECEPTOR BETA; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; DC-SPECIFIC ICAM-3 GRABBING NONINTEGRIN; IL6 PROTEIN, HUMAN; LECTIN; MEASLES MUMPS RUBELLA VACCINE; MOG PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; VIRUS ANTIBODY; VIRUS RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CD209 GENE; CELL ADHESION; CHILD; CONTROLLED STUDY; FEMALE; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREGULATION; INTERLEUKIN 6 GENE; MALE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN GENE; NECTIN 2 GENE; NORMAL HUMAN; PVR GENE; RETINOIC ACID RECEPTOR BETA GENE; RUBELLA VACCINATION; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION; VIRUS ATTACHMENT; VIRUS ENTRY; BIOSYNTHESIS; COHORT ANALYSIS; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; RUBELLA; RUBELLA VIRUS; VIROLOGY;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL ADHESION MOLECULES; CHILD; COHORT STUDIES; FEMALE; GENE EXPRESSION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, HUMORAL; INTERLEUKIN-6; LECTINS, C-TYPE; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE; RECEPTORS, RETINOIC ACID; RECEPTORS, VIRUS; RUBELLA; RUBELLA VIRUS; VACCINATION; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

EID: 84903273650     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099997     Document Type: Article

References (54)

1. Poland GA, Ovsyannikova IG, Kennedy RB, Haralambieva IH, Jacobson RM (2011) Vaccinomics and a New Paradigm for the Development of Preventive Vaccines Against Viral Infections. Omics 15: 625-636.
2. Haralambieva IH, Ovsyannikova IG, Pankratz VS, Kennedy RB, Jacobson RM, et al. (2013) The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Review of Vaccines 12: 57-70.
3. Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz SV (2001) Twin studies of immunogenicity - determining the genetic contribution to vaccine failure. Vaccine 19: 2434-2439. (Pubitemid 32234254)
4. Haralambieva IH, Oberg AL, Ovsyannikova IG, Kennedy RB, Grill DE, et al. (2013) Genome-wide characterization of transcriptional patterns in high and low antibody responders to rubella vaccination. PLos ONE 8: e62149.
5. Pankratz VS, Vierkant RA, O'Byrne MM, Ovsyannikova IG, Poland GA (2010) Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. BMC Immunol 11: 48.
6. Dhiman N, Haralambieva IH, Kennedy RB, Vierkant RA, O'Byrne MM, et al. (2010) SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine. Immunogenetics 62: 197-210.
7. Haralambieva IH, Dhiman N, Ovsyannikova IG, Vierkant RA, Pankratz VS, et al. (2010) 2′-5′-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine. Hum Immunol 71: 383-391.
8. Ovsyannikova IG, Haralambieva IH, Dhiman N, O'Byrne MM, Pankratz VS, et al. (2010) Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J Infect Dis 201: 207-213.
9. Ovsyannikova IG, Dhiman N, Haralambieva IH, Vierkant RA, O'Byrne MM, et al. (2010) Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Human Genetics 127: 207-221.
10. Ovsyannikova IG, Jacobson RM, Vierkant RA, O'Byrne MM, Poland GA (2009) Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine 27: 6926-6931.
11. Cong H, Jiang Y, Tien P (2011) Identification of the myelin oligodendrocyte glycoprotein as a cellular receptor for rubella virus. Journal of Virology 85: 11038-11047.
12. Noyce RS, Bondre DG, Ha MN, Lin LT, Sisson G, et al. (2011) Tumor Cell Marker PVRL4 (Nectin 4) Is an Epithelial Cell Receptor for Measles Virus. PLoS Pathog 7: e1002240.
13. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, et al. (2011) Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 480: 530-533.
14. Lozach PY, Kuhbacher A, Meier R, Mancini R, Bitto D, et al. (2011) DC-SIGN as a receptor for phleboviruses. Cell Host & Microbe 10: 75-88.
15. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, et al. (2003) Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. The Journal of Experimental Medicine 198: 557-567. (Pubitemid 37040390)
16. Kamran N, Takai Y, Miyoshi J, Biswas SK, Wong JS, et al. (2013) Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells. PLos ONE 8: e54406.
17. He Y, Bowman VD, Mueller S, Bator CM, Bella J, et al. (2000) Interaction of the poliovirus receptor with poliovirus. Proceedings of the National Academy of Sciences of the United States of America 97: 79-84. (Pubitemid 30055787)
18. Warner MS, Geraghty RJ, Martinez WM, Montgomery RI, Whitbeck JC, et al. (1998) A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology 246: 179-189. (Pubitemid 28384071)
19. Struyf F, Martinez WM, Spear PG (2002) Mutations in the N-terminal domains of nectin-1 and nectin-2 reveal differences in requirements for entry of various alphaherpesviruses and for nectin-nectin interactions. Journal of Virology 76: 12940-12950. (Pubitemid 35386978)
20. Backovic M, Rey FA (2012) Virus entry: old viruses, new receptors. Current Opinion in Virology 2: 4-13.
21. Ovsyannikova IG, Haralambieva IH, Vierkant RA, O'Byrne MM, Jacobson RM, et al. (2011) The Association of CD46, SLAM, and CD209 Cellular Receptor Gene SNPs with Variations in Measles Vaccine-Induced Immune Responses-A Replication Study and Examination of Novel Polymorphisms. Human Heredity 72: 206-223.
22. Dhiman N, Cunningham JM, Jacobson RM, Vierkant RA, Wu Y, et al. (2007) Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. Journal of Allergy and Clinical Immunology 120: 666-672. (Pubitemid 47320741)
23. Clifford HD, Hayden CM, Khoo SK, Zhang G, Le Souef PN, et al. (2012) CD46 measles virus receptor polymorphisms influence receptor protein expression and primary measles vaccine responses in naive Australian children. ClinVaccine Immunol 19: 704-710.
24. Clifford HD, Richmond P, Khoo SK, Zhang G, Yerkovich ST, et al. (2011) SLAM and DC-SIGN measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine. Vaccine 29: 5407-5413.
25. Lambert ND, Pankratz VS, Larrabee BR, Ogee-Nwankwo A, Chen MH, et al. (2014) High-throughput Assay Optimization and Statistical Interpolation of Rubella-Specific Neutralizing Antibody Titers. Clinical and Vaccine Immunology 21: 340-346.
26. Lambert ND, Haralambieva IH, Ovsyannikova IG, Larrabee BR, Pankratz VS, et al. (2013) Characterization of humoral and cellular immunity to rubella vaccine in four distinct cohorts. Immunologic Research 58: 1-8.
27. Haralambieva IH, Salk HM, Lambert ND, Ovsyannikova IG, Kennedy RB, et al. (2014) Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts. Vaccine 32: 1946-1953.
28. Haralambieva IH, Ovsyannikova IG, Umlauf BJ, Vierkant RA, Pankratz SV, et al. (2011) Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine 29: 8988-8997.
29. Haralambieva IH, Ovsyannikova IG, Kennedy RB, Vierkant RA, Pankratz SV, et al. (2011) Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine 29: 7883-7895.
30. Haralambieva IH, Ovsyannikova IG, Dhiman N, Kennedy RB, O'Byrne M, et al. (2011) Common SNPs/Haplotypes in IL18R1 and IL18 Genes are Associated with Variations in Humoral Immunity to Smallpox Vaccination in Caucasians and African-Americans. Journal of Infectious Diseases 204: 433-441.
31. Chen MH, Zhu Z, Zhang Y, Favors S, Xu WB, et al. (2007) An indirect immunocolorimetric assay to detect rubella virus infected cells. Journal of Virological Methods 146: 414-418. (Pubitemid 350026654)
32. Cleveland WS, Gross E, Shyu WM (1992) Local regression models. In: Chambers JM, Hastie TJ, editors. Statistical Models: Wadsworth & Brooks/Cole.
33. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, et al. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74: 106-120. (Pubitemid 38085242)
34. Kennedy RB, Ovsyannikova IG, Pankratz VS, Haralambieva IH, Vierkant RA, et al. (2012) Genome-wide genetic associations with IFNgamma response to smallpox vaccine. Human Genetics 131: 1433-1451.
35. Haralambieva IH, Ovsyannikova IG, Kennedy RB, Larrabee BR, Shane Pankratz V, et al. (2013) Race and sex-based differences in cytokine immune responses to smallpox vaccine in healthy individuals. Human Immunology 74: 1263-1266.
36. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nature Genetics 38: 904-909. (Pubitemid 44141658)
37. Greenland S, O'Rourke K (2008) Meta-Analysis. In: Rothman KJ, Greeland S, Lash T, editors. Modern Epidemiology. 3rd ed: Lippincott Williams and Wilkins. 652.
38. Haralambieva IH, Ovsyannikova IG, O'Byrne M, Pankratz VS, Jacobson RM, et al. (2011) A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine 29: 4485-4491.
39. Ovsyannikova IG, Haralambieva IH, Vierkant RA, O'Byrne MM, Poland GA (2013) Associations between polymorphisms in the antiviral TRIM genes and measles vaccine immunity. Human Immunology 74: 768-774.
40. Kennedy RB, Ovsyannikova IG, Haralambieva IH, O'Byrne MM, Jacobson RM, et al. (2012) Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes. Vaccine 30: 2159-2167.
41. Ovsyannikova IG, Haralambieva IH, Vierkant RA, O'Byrne MM, Jacobson RM, et al. (2012) Effects of Vitamin A and D Receptor Gene Polymophisms/Haplotypes on Immune Responses to Measles Vaccine. Pharmacogenetics and Genomics 22: 20-31.
42. Ovsyannikova IG, Haralambieva IH, Vierkant RA, Pankratz VS, Poland GA (2011) The role of polymorphisms in toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Human Genetics 130: 547-561.
43. Kindberg E, Ax C, Fiore L, Svensson L (2009) Ala67Thr mutation in the poliovirus receptor CD155 is a potential risk factor for vaccine and wild-type paralytic poliomyelitis. Journal of Medical Virology 81: 933-936.
44. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, et al. (1996) DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4: 573-581. (Pubitemid 26233311)
45. Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M (2004) Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). Journal of Immunology 172: 3994-3998. (Pubitemid 38375210)
46. Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, et al. (2004) Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). International Immunology 16: 533-538. (Pubitemid 38489427)
47. Maier MK, Seth S, Czeloth N, Qiu Q, Ravens I, et al. (2007) The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens. European Journal of Immunology 37: 2214-2225. (Pubitemid 47250214)
48. Abeler-Dorner L, Swamy M, Williams G, Hayday AC, Bas A (2012) Butyrophilins: an emerging family of immune regulators. Trends in Immunology 33: 34-41.
49. Malcherek G, Mayr L, Roda-Navarro P, Rhodes D, Miller N, et al. (2007) The B7 homolog butyrophilin BTN2A1 is a novel ligand for DC-SIGN. Journal of Immunology 179: 3804-3811.
50. Alagarasu K, Damle IM, Bachal RV, Mulay AP, Shah PS, et al. (2013) Association of promoter region polymorphisms of CD209 gene with clinical outcomes of dengue virus infection in Western India. Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 17: 239-242.
51. Barkhash AV, Perelygin AA, Babenko VN, Brinton MA, Voevoda MI (2012) Single nucleotide polymorphism in the promoter region of the CD209 gene is associated with human predisposition to severe forms of tick-borne encephalitis. Antiviral Research 93: 64-68.
52. Mezger M, Steffens M, Semmler C, Arlt EM, Zimmer M, et al. (2008) Investigation of promoter variations in dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) (CD209) and their relevance for human cytomegalovirus reactivation and disease after allogeneic stem-cell transplantation. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 14: 228-234.
53. Villamor E, Fawzi WW (2005) Effects of vitamin a supplementation on immune responses and correlation with clinical outcomes. Clin Microbiol Rev 18: 446-464. (Pubitemid 40995111)
54. Mora JR, Iwata M, Von Andrian UH (2008) Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 8: 685-698.